These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 35001525)

  • 1. Idiopathic pulmonary fibrosis: Current and future treatment.
    Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; DeLeon J; Reiss AB
    Clin Respir J; 2022 Feb; 16(2):84-96. PubMed ID: 35001525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiopathic pulmonary fibrosis: Molecular mechanisms and potential treatment approaches.
    Glass DS; Grossfeld D; Renna HA; Agarwala P; Spiegler P; Kasselman LJ; Glass AD; DeLeon J; Reiss AB
    Respir Investig; 2020 Sep; 58(5):320-335. PubMed ID: 32487481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
    Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
    BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat.
    Maher TM; Strek ME
    Respir Res; 2019 Sep; 20(1):205. PubMed ID: 31492155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
    Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
    Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?
    Singh V; Ulasov I; Gupta S; Singh A; Roy VK; Kharwar RK
    Discov Med; 2024 Jan; 36(180):22-47. PubMed ID: 38273744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies.
    Selvarajah B; Platé M; Chambers RC
    Mol Aspects Med; 2023 Dec; 94():101227. PubMed ID: 38000335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
    Feng H; Zhao Y; Li Z; Kang J
    Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiopathic Pulmonary Fibrosis: Review of Current Knowledge.
    Muri J; Durcová B; Slivka R; Vrbenská A; Makovická M; Makovický P; Škarda J; Delongová P; Kamarád V; Vecanová J
    Physiol Res; 2024 Aug; 73(4):487-497. PubMed ID: 39264073
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
    Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
    Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
    Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
    Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre.
    Bargagli E; Piccioli C; Rosi E; Torricelli E; Turi L; Piccioli E; Pistolesi M; Ferrari K; Voltolini L
    Pulmonology; 2019; 25(3):149-153. PubMed ID: 30236523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pulmonary fibrosis.
    Koudstaal T; Wijsenbeek MS
    Presse Med; 2023 Sep; 52(3):104166. PubMed ID: 37156412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients.
    Proesmans VLJ; Drent M; Elfferich MDP; Wijnen PAHM; Jessurun NT; Bast A
    Lung; 2019 Oct; 197(5):551-558. PubMed ID: 31440832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
    Moodley Y; Corte T; Richeldi L; King TE
    Respirology; 2015 Apr; 20(3):389-94. PubMed ID: 25727967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current challenges in the diagnosis and management of idiopathic pulmonary fibrosis in Japan.
    Bando M; Chiba H; Miyazaki Y; Suda T
    Respir Investig; 2024 Sep; 62(5):785-793. PubMed ID: 38996779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Idiopathic pulmonary fibrosis: Diagnosis, biomarkers and newer treatment protocols.
    Patel H; Shah JR; Patel DR; Avanthika C; Jhaveri S; Gor K
    Dis Mon; 2023 Jul; 69(7):101484. PubMed ID: 36220705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antifibrotic therapy in patients with idiopathic pulmonary fibrosis undergoing lung transplant in the peri and post-operative period.
    Dorey-Stein ZL; Shapiro W; Zhao H; Cordova FC; Criner GJ; Galli JA
    Respir Med; 2021 Dec; 190():106599. PubMed ID: 34788735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
    Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
    Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.